Celgene Corp (CELG) 104.05 $CELG
Final Glance: Biotechnology companies
AP - 41 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 3.15% Sell Off
Comtex SmarTrend(R) - 2 hrs 3 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 104.05 (-3.38)
Watch for Celgene to Potentially Rebound After Falling 3.15% Yesterday
Comtex SmarTrend(R) - 2 hrs 3 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 104.05 (-3.38)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - 2 hrs 23 mins ago
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.64 (+2.64), ILMN: 180.50 (-4.50), BITA: 91.91 (+12.62), CELG: 104.05 (-3.38)
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:40PM CST
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 75.26 (-1.84), AKRX: 38.21 (+0.53), ADHD: 3.66 (+0.06), CELG: 104.05 (-3.38)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 305.43 (-12.55), NTES: 100.64 (+2.64), HAL: 55.08 (+1.29), BITA: 91.91 (+12.62), BHI: 59.89 (+1.14), CELG: 104.05 (-3.38)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 305.43 (-12.55), AMZN: 327.82 (+11.34), HAL: 55.08 (+1.29), ILMN: 180.50 (-4.50), BITA: 91.91 (+12.62), BHI: 59.89 (+1.14), CELG: 104.05 (-3.38)
Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Stocks Flat While Medical Issues Tumble
at Investor's Business Daily - Fri Nov 14, 11:04AM CST
Stocks were mixed and mostly unchanged going into the lunch hour Friday after a slightly-better-than-expected retail sales report lifted optimism in the stock market today. The Nasdaq rose 0.1%, while the S&P 500 and the Dow Jones industrial average...
SINA: 39.80 (-2.05), WB: 18.93 (-0.69), TUBE: 16.95 (-1.06), BITA: 91.91 (+12.62), CELG: 104.05 (-3.38)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.43 (-12.55), VRTX: 111.34 (-1.38), GILD: 102.06 (-2.14), ALXN: 188.76 (-4.83), AMGN: 157.68 (-3.17), IBB: 288.17 (-5.72), REGN: 395.20 (-7.43), CELG: 104.05 (-3.38)
Early Glance: Biotechnology companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 102.06 (-2.14), IBIO: 1.05 (-0.03), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CELG: 104.05 (-3.38)
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.27 (-0.14), SRPT: 15.32 (+0.13), ILMN: 180.50 (-4.50), CELG: 104.05 (-3.38)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.79 (-0.17), ILMN: 180.50 (-4.50), GSK: 45.74 (+0.08), CELG: 104.05 (-3.38)
Celgene Has Returned 14.4% Since SmarTrend Recommendation (CELG)
Comtex SmarTrend(R) - Thu Nov 13, 9:34AM CST
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on October 21st, 2014 at $94.56. In approximately 3 weeks, Celgene has returned 14.43% as of today's recent price of $108.20.
CELG: 104.05 (-3.38)
Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
Business Wire - Thu Nov 13, 7:00AM CST
While it may not be surprising that breast and lung cancers are top of mind when people hear the word "cancer," 60% of respondents to a recent six-country survey about cancer awareness know almost nothing about pancreatic cancer, a leading cancer killer. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the US and is projected to be the second highest cause of death from cancer in the US by 2020. The overall five-year survival rate in the US and Europe is less than 7%; this rate has been low for many years and is among the lowest for common cancers in the US and across most countries in Europe.
CELGZ: 3.28 (+0.10), CELG: 104.05 (-3.38)
ModernGraham Quarterly Valuation Of Celgene Corporation
Benjamin Clark - at Seeking Alpha - Wed Nov 12, 4:11PM CST
CELG: 104.05 (-3.38)
Final Glance: Biotechnology companies
AP - 41 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Look for Shares of Celgene to Potentially Rebound after Yesterday's 3.15% Sell Off
Comtex SmarTrend(R) - 2 hrs 3 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 104.05 (-3.38)
Watch for Celgene to Potentially Rebound After Falling 3.15% Yesterday
Comtex SmarTrend(R) - 2 hrs 3 mins ago
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $102.13 to a high of $107.65. Yesterday, the shares fell 3.1%, which took the trading range below the 3-day low of $106.54 on volume of 7.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 104.05 (-3.38)
Stock Market Treads Water; Earnings Drive BitAuto
at Investor's Business Daily - 2 hrs 23 mins ago
Stocks struggled for direction for most of the day Friday amid upbeat data on retail sales and consumer sentiment. But the main indexes ultimately ended mildly higher. The Nasdaq edged up 0.2%, thanks to strength in software and solar issues. But...
NTES: 100.64 (+2.64), ILMN: 180.50 (-4.50), BITA: 91.91 (+12.62), CELG: 104.05 (-3.38)
Synageva Up on New Phase III Data on Sebelipase Alfa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:40PM CST
Synageva BioPharma Corp. (GEVA) announced the presentation of new data from a phase III study on sebelipase alfa for LAL deficiency.
GEVA: 75.26 (-1.84), AKRX: 38.21 (+0.53), ADHD: 3.66 (+0.06), CELG: 104.05 (-3.38)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 305.43 (-12.55), NTES: 100.64 (+2.64), HAL: 55.08 (+1.29), BITA: 91.91 (+12.62), BHI: 59.89 (+1.14), CELG: 104.05 (-3.38)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 305.43 (-12.55), AMZN: 327.82 (+11.34), HAL: 55.08 (+1.29), ILMN: 180.50 (-4.50), BITA: 91.91 (+12.62), BHI: 59.89 (+1.14), CELG: 104.05 (-3.38)
Midday Glance: Biotechnology companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Stocks Flat While Medical Issues Tumble
at Investor's Business Daily - Fri Nov 14, 11:04AM CST
Stocks were mixed and mostly unchanged going into the lunch hour Friday after a slightly-better-than-expected retail sales report lifted optimism in the stock market today. The Nasdaq rose 0.1%, while the S&P 500 and the Dow Jones industrial average...
SINA: 39.80 (-2.05), WB: 18.93 (-0.69), TUBE: 16.95 (-1.06), BITA: 91.91 (+12.62), CELG: 104.05 (-3.38)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 305.43 (-12.55), VRTX: 111.34 (-1.38), GILD: 102.06 (-2.14), ALXN: 188.76 (-4.83), AMGN: 157.68 (-3.17), IBB: 288.17 (-5.72), REGN: 395.20 (-7.43), CELG: 104.05 (-3.38)
Early Glance: Biotechnology companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 102.06 (-2.14), AMGN: 157.68 (-3.17), CELG: 104.05 (-3.38)
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene
PR Newswire - Fri Nov 14, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ: CELG). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, November 13, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,652.79, up 0.23% and the NASDAQ Composite closed at 4,680.14, up 0.11%. The S&P 500 finished the session 0.05% higher at 2,039.33. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.78, down 0.10%, whereas the index has gained 10.85% in the previous three months. Register for your complimentary reports on these five stocks at:
GILD: 102.06 (-2.14), IBIO: 1.05 (-0.03), ARIA: 6.15 (-0.10), MNKD: 6.16 (-0.02), CELG: 104.05 (-3.38)
Sarepta Initiates Dosing for Study Evaluating Eteplirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:40PM CST
Sarepta (SRPT) announced that it has enrolled the first patient in an open label study on eteplirsen in non-ambulant Duchenne muscular dystrophy patients.
RNA: 11.27 (-0.14), SRPT: 15.32 (+0.13), ILMN: 180.50 (-4.50), CELG: 104.05 (-3.38)
Ligand/Glaxo Seek EU Nod for Severe Aplastic Anemia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 4:00PM CST
Ligand Pharma (LGND) announced the submission of a Marketing Authorisation Application to the European Medicines Agency by its partner GlaxoSmithKline for Revolade.
LGND: 57.79 (-0.17), ILMN: 180.50 (-4.50), GSK: 45.74 (+0.08), CELG: 104.05 (-3.38)
Celgene Has Returned 14.4% Since SmarTrend Recommendation (CELG)
Comtex SmarTrend(R) - Thu Nov 13, 9:34AM CST
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on October 21st, 2014 at $94.56. In approximately 3 weeks, Celgene has returned 14.43% as of today's recent price of $108.20.
CELG: 104.05 (-3.38)
Global Survey Finds That Pancreatic Cancer, a Leading Cause of Cancer Deaths, is Virtually Unknown by Many in Europe and US
Business Wire - Thu Nov 13, 7:00AM CST
While it may not be surprising that breast and lung cancers are top of mind when people hear the word "cancer," 60% of respondents to a recent six-country survey about cancer awareness know almost nothing about pancreatic cancer, a leading cancer killer. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the US and is projected to be the second highest cause of death from cancer in the US by 2020. The overall five-year survival rate in the US and Europe is less than 7%; this rate has been low for many years and is among the lowest for common cancers in the US and across most countries in Europe.
CELGZ: 3.28 (+0.10), CELG: 104.05 (-3.38)
ModernGraham Quarterly Valuation Of Celgene Corporation
Benjamin Clark - at Seeking Alpha - Wed Nov 12, 4:11PM CST
CELG: 104.05 (-3.38)
